All In Biotech

NDA 210656 · Pfizer

Daurismo

Glasdegib Maleate · Oral · Hedgehog Pathway Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 21, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

29

5 Phase 3, 1 recruiting

FAERS reports

474

443 serious, 193 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. DAURISMO is embryotoxic, fetotoxic, and teratogenic in animals [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ] . Conduct pregnancy testing in females of reproductive potential prior to initiation of DAURISMO treatment. Advise females of reproductive potential to use effective contraception during treatment with DAURISMO and for at least 30 days after the last dose [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ] . Advise males of the potential risk of DAURISMO exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with DAURISMO and for at least 30 days after the last dose to avoid potential drug exposure [see Warnings and...

What it is approved for

From the label in effect Dec 12, 2025.

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1 )

Mechanism: Glasdegib is an inhibitor of the Hedgehog pathway. Glasdegib binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction. In a murine xenotransplant model of human AML, glasdegib in combination with low-dose cytarabine, inhibited increases in tumor size and reduced the percentage of CD45+/CD33+ blasts in the marrow to a greater extent than glasdegib or low-dose cytarabine alone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
  • DAURISMO · GLASDEGIB MALEATE EQ 100MG BASE · TABLET, ORAL · Prescription
  • DAURISMO · GLASDEGIB MALEATE EQ 25MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glasdegib" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death111
  • febrile neutropenia69
  • pneumonia48
  • off label use34
  • neoplasm progression28
  • neutropenia24
  • sepsis15
  • toxicity to various agents13
  • electrocardiogram qt prolonged12
  • product use in unapproved indication11
  • septic shock11
  • decreased appetite10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20151
20163
201813
2019116
2020121
2021107
202245
202320
202422
202517
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Daurismo (Glasdegib Maleate)

2024 spending

$3.7M

Beneficiaries

75

174 claims

Per beneficiary

$48,711

$653.50 per unit

View as table
YearSpending
2020$6,592,363
2021$4,716,600
2022$4,576,168
2023$2,942,885
2024$3,653,309

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 35 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.